From: Comparison of hierarchical EMAX and NDLM models in dose-response for early phase clinical trials
Large monotonic effect | d = 1 Control | d = 2 2.60 | d = 3 4.17 | d = 4 5.40 | d = 5 5.92 | d = 6 6.20 | d = 7 7.76 | d = 8 9.52 |
---|---|---|---|---|---|---|---|---|
pMAX | ||||||||
Hierarchical | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.08 | 0.90 |
simple NDLM | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.13 | 0.24 | 0.61 |
2nd order NDLM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.97 |
Pr(Pd > Pl) | ||||||||
Hierarchical | 0.00 | 0.37 | 0.63 | 0.75 | 0.84 | 0.95 | 0.99 | 1.00 |
simple NDLM | 0.00 | 0.59 | 0.68 | 0.78 | 0.90 | 0.99 | 0.00 | 1.00 |
2nd order NDLM | 0.00 | 0.80 | 0.88 | 0.96 | 0.98 | 0.99 | 1.00 | 1.00 |
Pr(phaseIII success) | ||||||||
Hierarchical | 0.03 | 0.21 | 0.44 | 0.56 | 0.69 | 0.86 | 0.96 | 0.99 |
simple NDLM | 0.02 | 0.33 | 0.43 | 0.54 | 0.72 | 0.98 | 0.97 | 0.98 |
2nd order NDLM | 0.03 | 0.49 | 0.70 | 0.93 | 0.99 | 0.93 | 0.99 | 1.00 |